FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT GAO Confirms Gaps in Device Reporting for Morcellators, Other Devices
02/08/2017
 
 
TXT Price Sworn in as HHS Secretary; FDA Head Named Next?
02/10/2017
 
 
TXT Grassley Probing Orphan Drug Program ‘Misuses’
02/10/2017
 
 
TXT High Court Nominee Favorable on Preemption Doctrine
02/06/2017
 
 
TXT Many Positions at FDA Gain Exemption to Hiring Freeze
02/10/2017
 
 
TXT Stakeholders Ask ‘Intended Use’ Rule Stay and Reconsideration
02/09/2017
 
 
TXT Public Citizen Asks FDA to Ban HES Solutions
02/08/2017
 
 
TXT Provider Letter Guidance Out
02/08/2017
 
 
TXT Regulation ‘Trade-in’ Order Could Impact Cures Act: Attorneys
02/07/2017
 
 
TXT Since Our Last Issue ...
02/12/2017
 
 
TXT Product Approval Summaries
02/12/2017
 
 
TXT Latest Federal Register Notices
02/12/2017
 
 
TXT Mansfield Ditches FDA to Join Cancer Screening-developer Grail
02/10/2017
 
 
TXT Petition Seeks Removal of Blocks on Generic Seroquel
02/10/2017
 
 
TXT FDA Intragastric Balloon Alert
02/09/2017
 
 
TXT FTC Approves Final Valeant Order
02/09/2017
 
 
TXT Court Approves Regeneca Worldwide Consent Decree
02/09/2017
 
 
TXT FDA Approves Emflaza Duchenne Drug
02/09/2017
 
 
TXT No Panel Meeting for Portola Pharma Blood Thinner
02/09/2017
 
 
TXT Physio-Control Class 1 Recall of Likepak 15 Defibrillator
02/09/2017
 
 
TXT Grassley Wants Presidential Ceremony for Whistleblowers
02/08/2017
 
 
TXT Regulation Causes High Drug Prices: NCPA
02/08/2017
 
 
TXT Suit Challenges Trump’s Order on Regulations
02/08/2017
 
 
TXT Quality System Violations at Korea’s Neo Vision
02/07/2017
 
 
TXT Republicans Introduce ‘Right to Try’ Bill
02/07/2017
 
 
TXT China’s Implant Dental Technology Has QS Issues
02/07/2017
 
 
TXT Lieu Introduces DEVICE Act
02/07/2017
 
 
TXT Latest FDA Warning Letters
02/07/2017
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving